Following the non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025, the Company is facing an uncertain and adverse situation regarding the continuation ...

Merck & Co.'s first trial over the safety of its blockbuster cancer vaccine Gardasil was postponed mid-trial due to concerns that jurors might be influenced by media coverage surrounding the ...

A lawyer for the plaintiff in the case said Merck agreed to halting the trial because his team feared that extensive ...

President Trump told reporters that tariffs on pharmaceuticals would start at "25% or higher," but did not say when they ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Recently appointed HHS Secretary Robert F. Kennedy Jr. in 2018 helped bring several cases against vaccine maker Merck, ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate, securing itself a shot ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.